NCT00079612View on ClinicalTrials.gov

Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

501

Participants

Timeline

Start Date

September 30, 2002

Study Completion Date

January 31, 2007

Conditions
Carcinoma, Renal Cell
Interventions
DRUG

Sorafenib (Nexavar, BAY43-9006)

800mg daily (2x 400mg tabs)

DRUG

Placebo

2x 400mg tabs daily

Trial Locations (7)

19104

Philadelphia

60637

Chicago

77030

Houston

78229

San Antonio

SW3 6JJ

London

G11 6NT

Glasgow

SM2 5PT

Sutton

Sponsors

Lead Sponsor

Bayer

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Bayer

INDUSTRY